Biotech — is developing non-systemic oral biologics to treat patients with gastrointestinal disorders. Focused on developing its lead drug product candidate, MS1819, a recombinant lipase enzyme that treats exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. AzurRx is headquartered in New York, NY, with scientific operations in Langlade, France, and clinical operations in Hayward, California.
AzurRx is listed on the NASDAQ under the symbol AZRX.
For more information about AzurRx BioPharma, please contact Martin Krusin, SVP of Corporate Development at (646) 713-2924